Fri, Jul 25, 2014, 3:01 AM EDT - U.S. Markets open in 6 hrs 29 mins

Recent

% | $
Click the to save as a favorite.

WisdomTree Japan Hedged Equity Message Board

becometernal 6 posts  |  Last Activity: Jun 29, 2014 8:51 PM Member since: Mar 22, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Alibaba Buy Out

    by goodtwogo1 Jun 27, 2014 12:55 PM
    becometernal becometernal Jun 29, 2014 8:51 PM Flag

    I was thinking the same thing. I don't think it is likely, but it would be a very good fit for a company with a strong China presence.

  • becometernal by becometernal Jun 2, 2014 8:25 PM Flag

    Light In The Box hired a noted wedding dress designer today. I found out through an alert service, but no word so far from state side media.

  • becometernal becometernal May 23, 2014 5:25 PM Flag

    This way too low. . . GILD is going to make over $7 next year. The real forward PE is more like 11 with a growth rate of 17.

  • becometernal by becometernal May 21, 2014 8:10 PM Flag

    Eric Jackson mentioned on CNBC that a stake in Baidu may be on Google shopping list. Please don't sell the golden goose. I want to ride this thing to $1,000.

    http://www.cnbc.com/id/101694923

  • Reply to

    Raymond James

    by escower May 13, 2014 7:12 AM
    becometernal becometernal May 13, 2014 8:18 AM Flag

    Easy money at these levels.

  • Released today. GILD is so cheap. I don't understand why someone doesn't buy it.

    Gilead announces results of HARMONY study showing reduction in AFB
    Gilead Sciences announced results from HARMONY, a randomized, double-blind, placebo-controlled Phase 2 study evaluating the effect of ranolazine and low-dose dronedarone, each given alone and in combination, on atrial fibrillation burden, AFB, in patients with paroxysmal atrial fibrillation, AF. In HARMONY, the combination of ranolazine and low-dose dronedarone provided greater reductions in AFB from baseline than either therapy used alone. Detailed results from the study will be presented today during a late-breaking clinical trials session at the annual meeting of the Heart Rhythm Society in San Francisco. Ranolazine is approved in the United States under the tradename Ranexa for the treatment of chronic angina at marketed doses of 500 mg and 1,000 mg twice daily. Ranexa with or without dronedarone is not approved for the treatment of AF. In the study, patients in the ranolazine 750 mg / dronedarone 150 mg and ranolazine 750 mg / dronedarone 225 mg arms experienced respective reductions of 45% and 59% in AFB from baseline over 12 weeks. Among patients receiving RD225, 45 percent achieved AFB reductions from baseline of =70 percent over 12 weeks. Neither ranolazine 750 mg nor dronedarone 225 mg alone caused statistically significant reductions in AFB from baseline compared to placebo. These results are consistent with pre-clinical findings of a synergistic effect when these therapies are used in combination.

DXJ
49.77-0.01(-0.02%)Jul 24 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.